Introgen Therapeutics (INGNQ) Inactive 10-Q2007 Q1 Quarterly report

Filed: 4 May 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: absent, advice, amenable, ancillary, andCancer, anticancer, antitumor, Asia, assay, Austin, Avenue, bioactive, biomedical, bona, borrow, bortezemib, CEO, certified, choose, circulation, classification, compliant, consecutive, contrast, criterion, culture, cumulatively, cytotoxic, decade, deemed, deposit, depreciation, derecognition, description, distant, electronic, endothelial, engineered, entity, exceeded, exceeding, exempt, exempted, exemption, exemptive, facie, FASB, fide, FIN, footnote, frame, front, harbor, heat, housing, hypodermic, input, intent, Internet, intravenously, IRI, IV, jurisdiction, Kingdom, line, long, maximum, MDACC, methotrexate, MHRA, Monitory, movement, Nasdaq, noncancellable, onForm, outfitted, peptide, pivotal, powerful, prima, provision, publicationCancer, publicationMolecular, QP, qualitative, quantitative, randomized, rapid, rapidly, reconciliation, regain, regularly, reinvesting, reinvestment, relieved, renal, return, Rule, scheduled, Secretary, shift, shock, shrinking, Silence, siRNA, situation, steroidal, succinate, Suite, syringe, taxable, telephone, thirteen, threshold, transient, UK, unavailable, undergo, unfavorable, Union, uptake, vascular, Velcade, VES, vitamin, website, Wise

Removed: ADVEXIN®therapy, anniversary, APB, assumed, bank, Bulletin, calculate, cancelled, charged, collaborator, computing, constituted, controlling, conversion, converted, convertible, coupon, daily, defining, determining, efficient, equivalent, Excluded, exercised, exploit, exploring, featured, forma, granting, hopeful, Immunopharmacolgy, intangible, intratumoral, intrinsic, issuable, merger, originating, oropharynx, ownership, par, periodically, plain, potently, principle, pro, pronouncement, recognizing, recording, remission, reorganization, repeated, represented, resale, resell, reserved, security, settlement, shortcut, smaller, spread, substituted, successor, surgically, TherapyandCancer, treasury, undesignated, unissued, vanilla, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

INGNQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, David G. Nance, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Introgen Therapeutics, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2007 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents in all material respects the financial condition and results of operations of Introgen Therapeutics, Inc.


Date: May 4, 2007	By:	/s/ DAVID G. NANCE

	Name:	David G. Nance
	Title:	Chief Executive Officer

I, James W. Albrecht, Jr., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Introgen Therapeutics, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2007 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents in all material respects the financial condition and results of operations of Introgen Therapeutics, Inc.


Date: May 4, 2007	By:	/s/ JAMES W. ALBRECHT, JR.

	Name:	James W. Albrecht, Jr.
	Title:	Chief Financial Officer